AbCellera Biologics Inc. (ABCL) Key Metrics
ABCL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.82B
- Enterprise value
- $3.59B
- P/E (TTM)
- —
- Forward P/E
- 27.5
- PEG ratio
- —
- Price / sales
- 57.8 10-yr median 36.7
- Price / book
- 4.5 10-yr median 2.0
- EV / EBITDA
- 5.3
- Dividend yield
- —
- Beta
- 1.41
ABCL key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsABCL valuation Price multiples at each fiscal year-end price.
Price / sales−54.5%
13.6
2025 · hover or tap a bar for each year
20182025
Price / book+29.4%
1.1
2025 · hover or tap a bar for each year
20182025
Free cash flow yield+4.6 pts
−17.0%
2025 · hover or tap a bar for each year
20182025
ABCL returns How much profit the business earns on the capital it uses.
Return on equity+0.3 pts
−14.5%
2025 · hover or tap a bar for each year
20182025
Return on invested capital+19.5 pts
−32.0%
2025 · hover or tap a bar for each year
20182025
Return on assets+0.7 pts
−10.8%
2025 · hover or tap a bar for each year
20182025
Free cash flow margin+416.7 pts
−231.7%
2025 · hover or tap a bar for each year
20182025
Asset turnover+173.1%
0.06
2025 · hover or tap a bar for each year
20182025
ABCL per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+156.7%
$0.25
2025 · hover or tap a bar for each year
20182025
Earnings per share
−$0.49
2025 · hover or tap a bar for each year
20182025
Free cash flow per share
−$0.58
2025 · hover or tap a bar for each year
20182025
Book value per share−9.8%
$3.24
2025 · hover or tap a bar for each year
20182025
Shares outstanding+1.5%
298.7M
2025 · hover or tap a bar for each year
20182025
ABCL financial health Debt, liquidity and how easily interest is covered.
Debt / equity+139.3%
0.15
2025 · hover or tap a bar for each year
20182025
Net debt+$169.6M
−$390.6M
2025 · hover or tap a bar for each year
20182025
Current ratio+15.5%
11.32
2025 · hover or tap a bar for each year
20182025
Debt / assets+119.7%
0.11
2025 · hover or tap a bar for each year
20182025
ABCL efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−394 days
596 days
2025 · hover or tap a bar for each year
20182025
Days of inventory
40 days
2025 · hover or tap a bar for each year
20182025
Days payables outstanding+265 days
377 days
2025 · hover or tap a bar for each year
20182025
Cash conversion cycle−621 days
259 days
2025 · hover or tap a bar for each year
20182025
Capex / revenue−215.0 pts
56.9%
2025 · hover or tap a bar for each year
20182025
ABCL valuation history
Fiscal year-endToday8-year median
ABCL returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ABCL debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ABCL cash returned to shareholders
DividendsBuybacksFree cash flow
ABCL price vs earnings per share
Share price at year-endEPS (right axis)
ABCL key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $1.02B | $862.4M | $1.65B | $3.19B | $4.55B | $10.59B | — | — |
| Enterprise value | $631.0M | $302.1M | $967.9M | $2.38B | $3.87B | $10.00B | — | — |
| P/E ratio | — | — | — | 20.1 | — | 89.0 | — | — |
| Price / sales | 13.6 | 29.9 | 43.4 | 6.6 | 392.0 | 45.4 | — | — |
| Price / book | 1.1 | 0.8 | 1.4 | 2.6 | 4.4 | 12.7 | — | — |
| Price / free cash flow | — | — | — | 15.6 | 24.5 | — | — | — |
| Price / operating cash flow | — | — | — | 11.5 | 18.6 | 466.7 | — | — |
| EV / sales | 8.4 | 10.5 | 25.5 | 4.9 | 333.2 | 42.9 | — | — |
| EV / EBITDA | — | — | — | 9.2 | — | 59.0 | — | — |
| EV / free cash flow | — | — | — | 11.7 | 20.8 | — | — | — |
| Earnings yield | −14.3% | −18.9% | −8.9% | 5.0% | −0.0% | 1.1% | — | — |
| Free cash flow yield | −17.0% | −21.7% | −7.4% | 6.4% | 4.1% | 0.1% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | — | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $3.42 | $2.93 | $5.71 | $10.13 | $14.30 | $40.24 | — | — |
| Per share | ||||||||
| Revenue per share | $0.25 | $0.10 | $0.13 | $1.54 | $0.04 | $0.89 | $0.05 | $0.06 |
| Earnings per share | −$0.49 | −$0.55 | −$0.51 | $0.50 | −$0.01 | $0.45 | −$0.01 | $0.00 |
| Operating cash flow per share | −$0.44 | −$0.37 | −$0.15 | $0.88 | $0.77 | $0.09 | $0.01 | $0.02 |
| Free cash flow per share | −$0.58 | −$0.64 | −$0.42 | $0.65 | $0.58 | $0.03 | −$0.01 | −$0.01 |
| Cash per share | $1.79 | $2.13 | $2.63 | $2.82 | $2.27 | $2.26 | $0.03 | $0.07 |
| Book value per share | $3.24 | $3.59 | $3.98 | $3.92 | $3.22 | $3.16 | $0.04 | $0.08 |
| Tangible book value per share | $2.95 | $3.28 | $3.40 | $3.35 | $2.61 | $2.60 | $0.04 | $0.08 |
| Dividends per share | — | — | — | — | — | — | $0.00 | — |
| Capex per share | $0.14 | $0.27 | $0.27 | $0.23 | $0.18 | $0.06 | $0.02 | $0.04 |
| Debt per share | $0.48 | $0.22 | $0.27 | $0.26 | $0.13 | $0.03 | $0.03 | $0.02 |
| Shares outstanding | 298.7M | 294.3M | 289.2M | 314.8M | 318.3M | 263.1M | 237.7M | 151.0M |
| Change in shares outstanding | +1.5% | +1.8% | −8.2% | −1.1% | +21.0% | +10.7% | +57.4% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −14.5% | −14.7% | −12.3% | 14.0% | −0.2% | 28.3% | −20.2% | 2.7% |
| Return on invested capital (ROIC) | −32.0% | −51.5% | −41.7% | 37.2% | −1.1% | 93.0% | −45.8% | −8.2% |
| Return on assets (ROA) | −10.8% | −11.4% | −9.7% | 11.1% | −0.2% | 23.1% | −9.8% | 1.4% |
| Return on tangible assets | −11.5% | −12.8% | −11.1% | 11.6% | −0.2% | 13.8% | −9.4% | 1.4% |
| Free cash flow margin | −231.7% | −648.4% | −319.2% | 42.2% | — | 3.4% | −11.2% | −19.7% |
| Income quality (OCF / net income) | — | — | — | 1.75 | — | 0.19 | — | 11.54 |
| Financial health | ||||||||
| Total debt | $143.2M | $65.4M | $77.4M | $82.3M | $40.1M | $6.8M | $6.9M | $3.4M |
| Cash & short-term investments | $533.8M | $625.6M | $760.6M | $886.5M | $723.0M | $594.1M | $7.6M | $10.4M |
| Net debt | −$390.6M | −$560.2M | −$683.2M | −$804.2M | −$682.9M | −$587.3M | −$662,000 | −$7.0M |
| Debt / equity | 0.15 | 0.06 | 0.07 | 0.07 | 0.04 | 0.01 | 0.67 | 0.30 |
| Debt / assets | 0.11 | 0.05 | 0.05 | 0.05 | 0.03 | 0.01 | 0.29 | 0.16 |
| Net debt / EBITDA | — | — | — | −3.09 | — | −3.46 | — | −4.87 |
| Current ratio | 11.32 | 9.81 | 7.33 | 8.67 | 7.70 | 7.86 | 1.60 | 2.36 |
| Quick ratio | 11.23 | 9.81 | 7.32 | 8.65 | 7.69 | 7.85 | 1.58 | 2.36 |
| Interest coverage | — | — | — | 53.5 | -19.7 | 24.0 | -19.7 | -3.6 |
| Working capital | $663.9M | $674.8M | $753.0M | $907.2M | $809.1M | $709.8M | $4.7M | $8.7M |
| Invested capital | $576.3M | $495.8M | $469.1M | $429.1M | $342.8M | $243.2M | $9.6M | $4.6M |
| Tangible asset value | $880.7M | $966.2M | $984.1M | $1.05B | $829.5M | $683.9M | $10.3M | $11.6M |
| Net current asset value | $338.2M | $446.9M | $536.2M | $717.9M | $637.0M | $638.3M | −$596,000 | $5.3M |
| Graham number | — | — | — | $6.66 | — | $5.67 | — | $0.06 |
| Graham net-net per share | $0.88 | $1.33 | $1.64 | $2.09 | $1.77 | $2.20 | −$0.02 | $0.01 |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | — | — | — | $14,161 | — |
| Share buybacks (net) | — | — | — | — | $11,154 | $0 | $11,000 | — |
| Dividends + buybacks / free cash flow | — | — | — | — | 0.0% | 0.0% | — | — |
| Capex / revenue | 56.9% | 271.9% | 203.8% | 15.0% | 503.4% | 6.3% | 34.4% | 60.1% |
| Capex / operating cash flow | — | — | — | 26.2% | 23.9% | 64.7% | 148.4% | 148.9% |
| Capex / depreciation | 1.48 | 0.81 | 2.51 | 2.20 | 3.39 | 2.78 | 2.16 | 5.78 |
| Stock-based compensation / revenue | 74.3% | 234.4% | 168.8% | 10.2% | 263.9% | 3.6% | 7.7% | 7.0% |
| R&D / revenue | 248.7% | 580.1% | 462.0% | 22.2% | 534.5% | 12.6% | 87.1% | 65.7% |
| SG&A / revenue | 110.8% | 296.5% | 197.7% | 13.8% | 23.7% | 6.8% | 34.6% | 32.4% |
| Efficiency | ||||||||
| Days sales outstanding | 596.4 | 990.7 | 805.3 | 104.6 | 6,107.5 | 169.0 | 55.5 | 58.0 |
| Days of inventory on hand | 40.1 | — | 15.6 | 8.8 | 12.3 | 10.6 | 2.9 | 0.0 |
| Days payables outstanding | 377.3 | 112.6 | 238.3 | 81.7 | 89.2 | 60.3 | 57.1 | 95.5 |
| Cash conversion cycle (days) | 259.3 | 880.1 | 582.6 | 31.7 | 6,030.6 | 119.2 | 1.3 | -37.4 |
| Receivables turnover | 0.61 | 0.37 | 0.45 | 3.49 | 0.06 | 2.16 | 6.58 | 6.29 |
| Payables turnover | 0.97 | 3.24 | 1.53 | 4.47 | 4.09 | 6.06 | 6.40 | 3.82 |
| Inventory turnover | 9.10 | — | 23.41 | 41.47 | 29.56 | 34.56 | 124.09 | 5,803,000.00 |
| Asset turnover | 0.06 | 0.02 | 0.03 | 0.34 | 0.01 | 0.45 | 0.52 | 0.41 |
| Average receivables | $122.8M | $78.3M | $83.9M | $139.1M | $194.3M | $107.9M | $1.8M | $1.4M |
| Average payables | $29.8M | $29.9M | $20.2M | $14.9M | $11.1M | $4.5M | $1.6M | $1.5M |
| Average inventory | $3.2M | $553,500 | $1.3M | $1.6M | $1.5M | $785,500 | $81,500 | $1 |
| Intangibles / total assets | 6.4% | 6.6% | 11.3% | 11.6% | 14.9% | 14.6% | 0.0% | 0.0% |
Computed from ABCL's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ABCL valuation and financial ratios
AbCellera Biologics earned a return on equity of −14.5% and a return on invested capital of −32.0% in fiscal 2025. It ended the year with $143.2 million of debt and $533.8 million in cash and short-term investments, a net cash position of $390.6 million. The share count rose 97.8% from 151.0M to 298.7M over 7 years.
See the ABCL income statement, the ABCL chart for price history, or the ABCL stock overview for the latest quote and news.
ABCL key metrics FAQ
What is AbCellera Biologics's return on equity?
AbCellera Biologics's return on equity (ROE) was −14.5% in fiscal 2025: net income of -$146.4 million on average shareholders' equity of $1.0 billion.
What is AbCellera Biologics's ROIC?
AbCellera Biologics's return on invested capital was −32.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does AbCellera Biologics have?
AbCellera Biologics had total debt of $143.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.15 and more cash than debt.
What is AbCellera Biologics's free cash flow yield?
AbCellera Biologics generated -$174.1 million of free cash flow in fiscal 2025, a free cash flow yield of −17.0% on its market value at year-end ($1.0 billion).
What is AbCellera Biologics's current ratio?
AbCellera Biologics's current ratio was 11.32 at the end of fiscal 2025: current assets were 11.32 times current liabilities.